aureus in Biological Technology

Rib-X Pharmaceuticals Announces Presentations at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

... panel of methicillin-resistant Staphylococcus aureus . Details on the presentations and ... Staphylococcus aureus positives ... active against methicillin-resistant S. aureus , multidrug-resistant Streptococcus pneumoniae ...

Cepheid Announces Symposium Speakers and Program Highlights for 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

... carriage of Methicillin-Resistant Staphylococcus aureus Xpert(R) MRSA/SA BC ... test for Methicillin-Resistant Staphylococcus aureus and S. aureus in positive blood culture bottles ...

Roche to Introduce New LightCycler(R) MRSA Advanced Test in the EU

... detection of methicillin-resistant Staphylococcus aureus for better patient care PLEASANTON, Calif., ... of methicillin-resistant Staphylococcus aureus (MRSA) is now available with the CE Mark, ... About methicillin-resistant Staphylococcus aureus (MRSA) ...

NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results

... for nasal decolonization of Staphylococcus aureus , including MRSA (Methicillin Resistant Staphylococcus aureus ). In this study, two concentrations of a ... dose treatment group provided consistent S. aureus reduction below the baseline score throughout ...

Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing

... for tigecycline was 91.2%. Staphylococcus aureus was the most frequently isolated pathogen, ... collected. Approximately 70% (68/96) of the S. aureus isolates were methicillin-resistant (MRSA) and ... tigecycline, and levofloxacin against all S. aureus isolates were 0.06, 0.12, and 4 micrograms/mL, ...

Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA

... against methicillin-resistant Staphylococcus aureus (MRSA), multi-drug resistant Streptococcus ... The most common pathogens isolated were S. aureus (MSSA and MRSA), Streptococcus pyogenes, ... (methicillin-) resistant Staphylococcus aureus (MRSA) (Poster C2-1974)(3) Dr. R. Jones and ...

eGenomics Awarded First U.S. Patent Covering Rapid DNA Sequencing Technology Platform to Control Hospital-Acquired Infections

... methycillin-resistant strains of Staphylococcus aureus (MRSA) infections," comments Barry Kreiswirth, ... platform works equally well on all Staphylococcus aureus -- MSSA and MRSA. We are in the process of ... proprietary library of over 6000 analyzed S. aureus strains, as well as other infectious organisms. ...

Aureus Pharma Releases New Unified Knowledge Database

... and Proteases PARIS, August 18 /PRNewswire/ -- aureus Pharma, a leading provider of knowledge ... and Protease represents an exciting milestone for aureus Pharma. These powerful new products considerably ... said Jason Theodosiou, President and CEO of aureus Pharma. "Using AurSCOPE Knowledge ...

Aureus Pharma Releases AurPROFILER(R) - a New and Powerful Pharmacology Profiling Solution

... PARIS, August 18 /PRNewswire/ -- aureus Pharma, a leading provider of knowledge ... to bring additional value to researchers." aureus Pharma experts will demonstrate AurPROFILER at ... in Philadelphia, PA August 18th -21st. About aureus Pharma ...

Aureus Pharma Announces Date of 2008 Annual User Symposium

... PARIS, July 2 /PRNewswire/ -- aureus Pharma, a leading provider of knowledge ... life science industry, announced today that the aureus Pharma 2008 User Symposium will be held in Paris ... developments were discussed. At the 2008 event, aureus will introduce several new products and services ...

New approach may render disease-causing staph harmless

... new treatment strategy for serious Staphylococcus aureus (Staph) infections. The research, published Feb. ... pigment called a carotenoid gives the S. aureus bacterium its edge. aureus is Latin for golden. The carotenoid acts as an ...

Aureus Pharma Announces Renewal and Expansion of Licensing Agreement With Bristol-Myers Squibb for its AurSCOPE Knowledge Databases

... PARIS, November 12 /PRNewswire/ -- aureus Pharma, a leading provider of knowledge ... Kinase and Ion Channel Knowledge databases. aureus Pharma's target-family-based AurSCOPE knowledge ... very pleased that Bristol-Myers Squibb has chosen aureus Pharma as a partner for knowledge based drug ...

Tips from the Journals of the American Society for Microbiology

... Antimicrobial Agents and Chemotherapy. S. aureus is a highly flexible and potentially dangerous ... forty to sixty percent of reported nosocomial S. aureus infections in the United States and the United ... resistant with methicillin-resistant S. aureus carrying a significantly higher mortality rate. ...

New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA

... and resistant Staphylococcus aureus (MSSA and MRSA) bloodstream infections ... infections (cSSTI) caused by Staphylococcus aureus and other Gram positive bacteria, including ... (RIE) due to Staphylococcus aureus and Staphylococcus aureus bacteraemia (SAB) when ...

Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting

... Staphylococcus aureus and ... Staphylococcus aureus in ... Variant (SCV) of S. aureus ...

Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia

... alternative for the treatment of methicillin-resistant Staphylococcus aureus and other bacterial infections. Radezolid has been shown to be ... developing an IV/oral macrolide active against methicillin-resistant S. aureus , multidrug-resistant S. pneumoniae and S. pyogenes . In addition to ...

Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures

... System, for the detection of Methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus aureus (SA, typically methicillin susceptible) ... is methicillin-resistant or methicillin-susceptible Staphylococcus aureus -- are done via slower culture testing methods. "Same day diagnostic ...

Cepheid Receives FDA Clearance for First Rapid On-Demand Molecular Diagnostic Test for MRSA and S. aureus

... System, for the rapid detection of Methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus aureus (SA, typically Methicillin-sensitive) in skin and soft tissue infections. ...

Ondine Biopharma Announces Second Quarter 2008 Financial Results

... decolonization of potentially pathogenic bacteria such as Staphylococcus aureus and methicillin-resistant Staphylococcus aureus ("MRSA") in the nose, as well as for the decolonization of micro organisms ...

Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC

... commercial production for the treatment and prevention of Staphylococcus aureus infections. Terms of the manufacturing agreement were not disclosed. ... founded to develop a promising new treatment for serious Staphylococcus aureus infections, including those caused by methicillin-resistant strains known ...

Cepheid Reports Fourth Quarter and Full Year 2007 Results

... and community-acquired infections -- Methicillin Resistant Staphylococcus aureus (MRSA) and Staphylococcus aureus (SA). The tests, Xpert(TM) MRSA/SA-Blood Cultures (BC) and Xpert(TM) ...

Arpida-Supported CME Symposium Available Online

... symposium is entitled "Treatment of Methicillin-resistant Staphylococcus aureus and Other Resistant Infections: An Expert Debate". In it distinguished ... treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The US Food and Drug Administration has granted fast track status ...

Soap and Water May not be Enough to Fight MRSA Superbug

... from this strain of staph are on the rise. MRSA and Staphylococcus aureus are germs that live on the skin of healthy people and spread from person ... Management of Community-Acquired Methicillin-Resistant Staphylococcus aureus (CA- MRSA) Infections in the US Navy and Marine Corps," August ...

Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC

... to Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus (MRSA). These data are from the ATLAS (Assessment of TeLAvancin in ... response rates were typically higher for telavancin. Staphylococcus aureus is a common cause of surgical-site infections. Physicians report an ...

Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG

... a strategic partner for its NicVAX(R) and StaphVAX(R) (Staphylococcus aureus Polysaccharide Conjugate Vaccine) programs. Nabi also will retain the ... the NicVAX(R) (Nicotine Conjugate Vaccine) and StaphVAX(R) (Staphylococcus aureus Polysaccharide Conjugate Vaccine) development programs. For a complete ...

Celtic Pharma Holdings Announces Investment in Novacta Biosystems Limited

... potential drug candidates, including those in the C. difficile programme. Other programmes include one targeting methicillin-resistant Staphylococcus aureus (MRSA) infection and others targeting Gram-negative infections. For further information, please visit our website at www.novactabio.com . ...

Rib-X Pharmaceuticals, Inc. Appoints Dr. Russell Greig to Board of Directors

... Gram-negative bacteria and the Rx-02 discovery program is focused on developing an IV/oral macrolide active against methicillin-resistant S. aureus , multidrug-resistant Streptococcus pneumoniae and S. pyogenes . For more information on the Rib-X mission and the pipeline, please visit ...

ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema

... for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus , including methicillin-resistant strains. ViroPharma commercializes Cinryze(TM) (C1 esterase inhibitor [human]) for routine prophylaxis against ...

ViroPharma to Present at Two June Healthcare Conferences

... for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus , including methicillin-resistant strains. ViroPharma commercializes Cinryze(TM) (C1 esterase inhibitor (human)) for routine prophylaxis against ...

ViroPharma Incorporated Honored by the National Organization for Rare Disorders

... for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus , including methicillin-resistant strains. ViroPharma commercializes Cinryze(TM) (C1 esterase inhibitor (human)) for routine prophylaxis against ...

ViroPharma Incorporated Reports First Quarter 2009 Financial Results

... for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus , including methicillin-resistant strains. ViroPharma commercializes Cinryze(TM) (C1 esterase inhibitor (human)) for routine prophylaxis against ...

ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009

... for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus , including methicillin-resistant strains, and Cinryze(TM) (C1 inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent ...

Intercell Announces European Approval of New Vaccine, IXIARO(R), to Prevent Japanese Encephalitis

... the Statens Serum Institut. The Company's development pipeline includes Phase II vaccine programs for Pseudomonas (in-house development) and S. aureus , which is being developed with Merck & Co. Inc. The Company's novel Travelers' Diarrhea vaccine patch will enter Phase III testing in 2009. ...

ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes

... for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus , including methicillin-resistant strains, and Cinryze(TM) (C1 inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent ...

Lakewood-Amedex, Inc. Appoints William J. Robison, Former Executive Vice President of Pfizer, as Board Member

... proven to be effective against a wide range of bacteria, encompassing antibiotic resistant strains including methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas and others, and patents covering certain proprietary products targeting pandemic viral infections including, Epstein Barr ...

ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results

... for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus , including methicillin-resistant strains. ViroPharma commercializes Cinryze(TM) (C1 inhibitor (human)) for routine prophylaxis against angioedema ...

Tips from the journals of the American Society for Microbiology

... from 3 to 33% of lactating mothers and of those incidences 75 to 95% are diagnosed within the first twelve weeks postpartum. While Staphylococcus aureus and Staphylococcus epidermidis are considered to be the main infectious agents associated with mastitis, increased multi-drug resistance to ...

Tips from the journals of the American Society for Microbiology

... from 3 to 33% of lactating mothers and of those incidences 75 to 95% are diagnosed within the first twelve weeks postpartum. While Staphylococcus aureus and Staphylococcus epidermidis are considered to be the main infectious agents associated with mastitis, increased multi-drug resistance to ...

Cepheid Molecular Diagnostic Test for MRSA and S. aureus Categorized 'Moderate Complexity' by FDA

... under the Clinical Laboratory Improvement Amendments (CLIA). The new test is designed for on-demand detection of Methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus aureus (SA), (typically Methicillin-sensitive) in SSTIs. Xpert MRSA/SA SSTI runs on Cepheid's GeneXpert(R) System, the ...

Great Basin Scientific, Inc. Closes $3.9 Million in Equity Funding

... the spring of 2009 as it completes the design of its rapid molecular diagnostic testing platform and brings a methicillin-resistant Staphylococcus aureus (MRSA) test into clinical trials. The silicon chip based technology is simple, cost-effective and improves on the highly complex, traditional ...